Combination therapy with anti-HIV drugs and opportunistic infection drugs is a common practice in treatment of AIDS patients. Although toxic effects of most individual therapies are known, the toxic potential of most combination therapies has not been established. To understand the toxic consequences of combination therapies, the commonly used anti-HTV drug 3'-azido-3'-deoxythymidine (AZT) and tuberculosis infection therapies pyrazinamide, isoniazid, and rifampicin were evaluated by 13-week gavage studies in B6C3F1 mice, either alone or AZT in combination with one of the antituberculosis drugs. The doses include AZT 100, 200, and 400; pyrazinamide 1000 and 1500; isoniazid 50,100, and 150; and rifampicin 100, 200, and 400 mg/kg/day. AZT alone caused hematopoietic toxicity with dose-related bone marrow suppression, macrocytic anemia, and thrombocytosis. Pyrazinamide or isoniazid alone at the doses tested did not cause significant toxicity. Rifampicin alone caused hematopoietic toxicity and possibly mild hepatic toxicity. Pyrazinamide below 10 times the therapeutic dose when given with AZT did not increase the hematological toxicity of AZT. Isoniazid markedly increased the hematological toxicity of AZT and contributed to mortality at 3 to 4 times the therapeutic dose combinations. Administration of rifampicin with AZT at the calculated therapeutic doses resulted in toxicity of far greater magnitude than that caused by AZT or rifampicin alone. Combination treatment with AZT and rifampicin caused severe anemia with mortality at 2 to 4 times the therapeutic dose combinations. However, AZT did not enhance the hepatotoxkity of rifampicin. Increased hematopoietic toxicity of AZT when given in combination with the above antituberculosis drugs may be due to changes in the metabolism of AZT. Results of these studies indicate that toxicological effects of combination therapies could be considerably more severe than and different from the toxicity of individual therapies.
The acquired immune deficiency syndrome (AIDS) is a multisystem disease that has become a major public health problem since 1981. The primary etiologic agent of AIDS is a retrovirus, referred to as the human immunodeficiency virus (HIV). The effective therapy of patients infected with HIV depends on the ability of drugs to prevent or impair the replicating mechanisms of the retrovirus without affecting the host. Dideoxynucleosides and nucleoside analogues are phosphorylated by cellular kinases and inhibit viral replication by acting as DNA chain terminators and inhibitors of retroviral specific reverse transcriptase. Zidovudine (3'-azido-3'-deoxythymidine, AZT, Retrovir) has been the most commonly used dideoxynucleoside for treatment of HIV-positive patients. Adverse effects of AZT therapy are myelosuppression and anemia (Richman, 1988; Amin, 1989; Pluda et al, 1991) . Toxic mitochondrial myopathy was also observed in patients on longterm AZT therapy (Balzarini, 1994) . In B6C3F1 mice AZT caused hematological changes by Day 5 at 1000 mg/kg/day, with dose-and duration of treatment-related anemia including myelosuppression by 13 weeks. The effects were more severe in females than in males. Hematological effects either reversed or dramatically improved within 30 days of stopping treatment (Thompson et al, 1991) .
Since HIV infection causes immunodeficiency, the majority of AIDS patients die from opportunistic infections. One of the most common opportunistic infections leading to mortality of AIDS patients is tuberculosis (TB) caused by Mycobacterium tuberculosis or Mycobacterium avium complex (MAC). HIVpositive patients with tuberculosis have received combination therapy with AZT and antituberculosis drugs such as pyrazinamide, isoniazid, rifampicin, and others.
Hepatotoxicity is the most common side effect of pyrazinamide treatment in humans. Mild and transient asymptomatic increases in serum hepatic enzymes are common in antituberculosis therapy (Ramakrishnan et al., 1968; Baron and Bell, 1974) . However, in about 15% of patients symptoms of hepatic disease (jaundice) occur, and in rare instances death due to hepatic necrosis has been observed in patients on pyrazinamide therapy (Mandell and Sande, 1990) . The therapeutic dose of pyrazinamide for treatment of experimental tuberculosis in mice is 150 mg/kg (Grosset et al., 1992) . No apparent hematological, reproductive, or developmental toxicity was observed in female Swiss (CD-I) mice administered pyrazinamide at 1200 mg/kg/day (approximately eight times the " In mg/kg/day (human or mouse therapeutic dose equivalent). * Evaluated either alone or in combination with AZT only. NT, not tested. therapeutic dose) for 30 days (National Institute of Environmental Health Sciences, 1997).
Isoniazid has been used for the treatment of tuberculosis since 1951. Primary toxic effects associated with isoniazid therapy in humans include low incidences of rash, fever, jaundice, and peripheral neuropathy (Mandell and Sande, 1990) . The reported LD50 value of isoniazid for mice by the oral route is 133 mg/kg (Benson et al, 1952) . Isoniazid has caused hepatotoxicity and peripheral neuropathy in rodents (Timbrell, 1981; Blakemore, 1980) . Pregnant mice treated with isoniazid up to 88 mg/kg had early resorptions and embryolethality but no teratological changes (Menon and Bhide, 1980) . Toxicity with mortality occurred in Fl mice when treated with 88 mg/kg/day during gestation, lactation, and postweaning periods (Menon and Bhide, 1983) . Contrary to the above reports, isoniazid did not cause significant hematological, reproductive, and developmental toxicity in female Swiss (CD-I) mice up to 150 mg/kg/day when administered by gavage for 30 days (National Institute of Environmental Health Sciences, unpublished report). However, isoniazid at 150 mg in combination with AZT at 400 mg/kg/day increased the hematological toxicity of AZT in the above study.
Rifampicin is a semisynthetic derivative of rifamycin-B. The most common adverse effects of rifampicin therapy are nausea, vomiting, fever, and rash (Grosset and Leventis, 1983) . However, jaundice has been observed in some patients (Scheuer et al, 1974) . Rifampicin is a potent inducer of hepatic microsomal enzymes (Ohanhaus et al, 1979) and decreases the halflife of a number of therapeutic agents (O'Reilly, 1975; Buffington et al, 1976) . The oral LD50 for the mouse is 885 mg/kg (Furesz, 1970) . Animal studies suggest that a combination of rifampicin and isoniazid but not rifampicin alone may cause liver toxicity. Hepatic lesions were not observed in mice treated with rifampicin at 25 or 50 mg/kg for 4 weeks (Balea et al, 1970) .
Literature review indicates that toxicity profiles of individual therapies (especially opportunistic infection therapies) in animal models are available for some drugs and incomplete for others. Furthermore, the toxic potential of combination therapies has not been established. The purpose of our studies is to determine the toxic consequences of the antituberculosis drugs pyrazinamide, isoniazid, and rifampicin when given in combination with AZT to B6C3F1 mice for 13 weeks.
MATERIALS AND METHODS
Animals and animal care, B6C3F1 mice were produced in a pathogenfree production colony of the National Institute of Environmental Health Sciences (NIEHS) at Taconic Farms, Inc. (Germantown, NY). Mice were received at the Southern Research Institute when they were 4 weeks of age. After quarantine and acclimation for 2 weeks, they were determined to be pathogen free and were subsequently weighed, stratified by weight, and randomly distributed to treatment and control groups. Males (one per cage) and females (five per cage) were housed in hanging drawer-type polycarbonate cages with solid bottom and sides (See-Through Systems, Lab Products, Inc., Maywood, NJ). Cages were suspended from perforated stainless-steel shelves covered with filter fabric. Heat-treated hardwood bedding was used as contact bedding. Municipal drinking water was provided ad libitum by an automated watering system (Edstrom Industries, Inc., Waterford, WT). The N1H-07 diet (Zeigler Bros., Inc., Gardners, PA), in pelleted form was fed ad libitum. Animal use and care were in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals (National Research Council, 1985) . The studies were conducted at the Southern Research Institute, a facility accredited by the Association for Assurance and Accreditation of Laboratory Animal Care International (Rockville, MD), with protocols approved by Southern Research Institute's Animal Care and Use Committee.
Therapeutic agents and study design. AZT (CAS 30516-87-1) and rifampicin (CAS 13292-46-1) were manufactured by Raylo Chemicals (Edmonton, Alberta). Pyrazinamide (98-96-4) was obtained from Aldrich Chemical Company (Milwaukee, WI), and isoniazid (CAS 54-85-3) was manufactured by Fluka Chemical Corporation (Ronkonkoma, NY). The purity of AZT, pyrazinamide, and isoniazid was s99%, and that of rifampicin was £97%, as determined by infrared and nuclear magnetic resonance spectrometry. The experimental design with treatment groups, dosages, and mouse therapeutic dose equivalents for pyrazinamide (Grosset et al., 1992) and human therapeutic dose equivalents for other drugs as estimated by surface area (Freireich et al., 1966) are given in Table 1 . Since pyrazinamide did not cause hematological toxicity in female Swiss mice at 1200 mg/kg/day (eight times the therapeutic dose) for 30 days, doses below and above the nontoxic dose of pyrazinamide were selected for evaluation in combination with AZT. The literature indicates that isoniazid and rifampicin are more toxic than pyrazinamide. Therefore, one to four times the therapeutic doses of isoniazid and rifampicin were selected for evaluation of combination therapy toxicity with AZT.
There were 20 mice of each sex per treatment or control group, with 10 mice for the 13-week core study and 10 mice from which blood was obtained from the retroorbital sinus under CO 2 + O 2 (70% + 30%) anesthesia for hematology on Days 4, 30, and 60 of the study. The selected doses of individual drugs or combination therapies were given by gavage in 0.5% methyl cellulose in water suspension as the vehicle in a volume of 20 ml/kg/day. The daily dose was divided into two equal doses and administered to the mice at least 6 h apart, at approximately the same time each day (morning and afternoon). Dose formulations of individual drugs and combination therapies analyzed during the course of the studies contained an average of more than 90% of the expected concentration of the drugs.
Observations. All mice were observed twice daily (morning and afternoon) for moribundity and mortality. Clinical signs and body weights were recorded before the first dose and at weekly intervals thereafter. Blood was obtained on Days 4, 30, and 60 from hematology groups and prior to sacrifice on Days 92-95 from the 13-week core study groups by the procedure described above. Blood for hematology was collected into a tube containing EDTA and blood for clinical chemistry was collected into a tube with no anticoagulant. Erythrocyte (RBC), platelet, and leukocyte counts, hematocrit, hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and differential leukocyte counts were determined on whole blood using the Technicon H • 1 automated hematology analyzer (Bayer Corp., Tarrytown, NY). Reticulocyte counts were determined with a Coulter Model Elite Flow Cytometer (Coulter Diagnostics, Hialeah, FL). Blood smears were prepared to manually verify differential leukocyte counts and erythrocyte and platelet morphology, if necessary. Depending on the quantity of sample available alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase, and bile acids of serum were determined using a Roche Cobas Fara analyzer (Roche Diagnostics, Nutley, NJ).
Mice from the 13-week study were euthanized with CO 2 and all mice of the core study group including those that died during the course of the study were subjected to complete necropsy and the tissues were fixed in neutral buffered formalin. Fixed tissues were processed, embedded in paraffin, sectioned at approximately 5 jun, and stained with hematoxylin and eosin. Sections of the following tissues were evaluated for histopathological changes by light microscopy: esophagus, stomach, pancreas, liver, gallbladder, large and small intestine, nose, trachea, lungs, bronchi, heart, aorta, spleen, thymus, lymph nodes, kidneys, urinary bladder, brain, pituitary, thyroid, parathyroids, adrenals, testes, epididymis, seminal vesicle, prostate, preputial glands, ovaries, uterus, clitoral glands, mammary gland with skin, femur including bone marrow, and gross lesions. These tissues were examined in all control mice, all mice in the highest dose group with at least 60% survival, and all mice in the next highest dose group inclusive of early deaths. Bone marrow, liver, spleen, and gross lesions of all mice in lower dose groups were also evaluated.
Statistical methods. Group means and standard deviations were calculated for body weights, hematology parameters, and terminal body and organ weights. Mean terminal body weights and mean organ weights of each treated group of each sex were compared with those of the corresponding control group by the two-tailed Fisher's least significant method (Snedecor and Cochran, 1967 ) for significant differences. Hematology parameters were evaluated by Dunnett's test (1955) for differences between the control and various dose groups and for differences between drug combinations and the corresponding dose of AZT. Interaction of AZT and anti-TB drugs on hematological toxicity, especially RBC count was evaluated by isobolograms (Berenbaum, 1985; Carter et al, 1988; Gennings et al., 1990) .
RESULTS AND DISCUSSION
Major targets for toxicity of AZT, antituberculosis drugs, and combinations of AZT and antituberculosis therapies include hematopoietic tissues and liver (Mandell and Sande, 1990; Richman, 1988; Timbrell, 1981; Scheuer et al., 1974) . Toxic effects of individual and combination therapies are described below. RBC counts and hemoglobin concentrations obtained at 30-, 60-, and 92-day samplings are listed in Tables  2 to 7 . Hematological parameters observed at the Day 4 sampling were not markedly different from the control values; therefore, they are not listed in the tables. Reticulocyte counts, calculated hematological parameters such as MCV and MCH, and leukocyte counts are not included in the tables but are described with each drug or combination when biologically significant changes were observed. AZT appears to have a unique effect on platelet counts; therefore, platelet counts obtained at the 30-, 60-, and 92-day samplings are listed in Tables 2 to 7. AZT AZT alone at 100, 200, and 400 mg/kg caused anemia, thrombocytosis, (Tables 2-7), reticulocytopenia followed by reticulocytosis, and leukopenia. Hematological toxicity was more severe in females than in males (Tables 2-7). The anemia was usually dose related, and exacerbated with increasing duration of treatment. Elevations of MCV and MCH values (not included in the tables) indicative of macrocytosis also occurred.
AZT + Pyrazinamide
AZT alone, pyrazinamide alone, or the combination at the doses tested did not cause a significant effect on body weight gain. Administration of pyrazinamide at 1000 and 1500 mg/kg did not cause any biologically significant changes in hematological parameters; however, minor statistically significant increases in hemoglobin concentration at the 92-day sampling were observed in mice of both sexes (Tables 2 and 3 ). Pyrazinamide at 1500 mg when coadministered with AZT at 400 mg/kg caused hematological changes more severe than those caused by AZT alone (Tables 2 and 3 ). These changes included significant decreases (p < 0.01) in RBC counts and significant increases (p < 0.01) in platelet counts (Tables 2 and 3 ). An initial reticulocytopenia (p < 0.01) on Day 4 followed by reticulocytosis (p < 0.01) on Days 30, 60, and 92 was observed, indicating the regenerative response of the hematopoietic system. Pyrazinamide did not markedly influence the cellular depletion of bone marrow caused by AZT alone. The individual and combination therapies at the doses tested did not cause significant changes in the selected serum enzymes evaluated in this study. AZT at 400 mg caused a significant increase in the incidence but not the severity of glycogen depletion in liver. Pyrazinamide, at the doses tested, caused increases in liver weights and increased the incidence and severity of liver glycogen depletion. These effects of pyrazinamide were not enhanced by coadministration of AZT.
Pyrazinamide up to 6.7 times the therapeutic dose (1000 mg/kg) did not markedly increase the toxicity of AZT up to 4 times (400 mg) the calculated therapeutic dose. However, 10 times the therapeutic dose of pyrazinamide increased the hematological toxicity of AZT at 4 times the calculated therapeutic dose as indicated by biologically significant decreases in RBC count and hemoglobin concentration (Tables 2 and 3) accompanied by a biologically significant reticulocytosis.
AZT + Isoniazid
AZT alone at 100, 200, and 400 mg/kg did not cause significant changes in body weight gain. AZT at 100 mg, when coadministered with isoniazid at 50 mg/kg, increased body weight gain in male mice. However, AZT at 400 mg with 150 mg/kg isoniazid significantly decreased body weight gain and caused mortality of female mice. Isoniazid alone at the doses tested did not cause consistent changes in hematological parameters in male and female mice (Tables 4 and 5 ). Isoniazid at 100 and 150 mg increased the severity of anemia and hematological changes of AZT at 400 mg/kg (Tables 4 and 5 ). These changes included dose-related decreases in RBC counts and hemoglobin concentrations contributing to mortality at the highest dose combination in female mice. More female mice of the hematology group in the highest dose combination died by Day 60 as compared with the 13-week core study group (Table  5 ). Hematological toxicity due to treatment exacerbated by repeated blood sampling (at Days 4 and 30) leading to severe anemia appears to be the cause of increased mortality of the highest dose combination hematology groups because repeated blood sampling at Days 4 and 30 did not change the hematological parameters of the control group at the Day 60 sampling (Table 5 ). The female mice in the highest dose combination group (400 mg AZT + 150 mg isoniazid) of the 13-week core study that did not die during the study appeared to be recovering as indicated by reticulocytosis (215% of control), with other hematological values not significantly different from those of the 400-mg AZT group at the Day 92 sampling (Table  5 ). The highest dose combination also caused a significant increase (p < 0.01) in platelets at 30 and 60 days (Tables 4 and  5 ). At 150 mg isoniazid alone did not cause significant changes in bone marrow cellularity, but when given in combination with AZT, it markedly increased the cellular depletion caused by AZT. The individual and combination therapies at the doses tested did not cause biologically significant changes in the selected serum enzymes evaluated in this study. Pigmentation in the Kupffer cells of liver, possibly related to metabolites of • Significantly different from control, p < 0.05. ** Significantly different from control, p < 0.01.
t Significantly different (p < 0.05) from the corresponding dose of AZT alone.
isoniazid, was seen in male (100 and 150 mg/kg groups) and, to a lesser extent, female (150 mg/kg group) mice. Isoniazid at 150 mg caused mild hepatocellular hypertrophy in some male mice. AZT did not enhance the isoniazid-associated changes in liver. Isoniazid at 2 times (100 mg) the therapeutic dose enhanced the hematological toxicity of AZT at 2 to 4 times the therapeutic doses. Isoniazid at 3 times the therapeutic dose appears to potentiate the hematological toxicity of AZT at 4 times the therapeutic dose. Hematological toxicity of combination therapy was more severe in females than in males and it may have contributed to mortality of females in the highest dose combination group by Week 8 (Tables 4 and 5 ). Since isoniazid caused morphological changes in hepatocytes, the enhancement of hematological toxicity of AZT may be related to changes in metabolism of AZT in the liver.
ATT + Rifampicin
Rifampicin alone caused a significant decrease in body weight gain only at 400 mg and AZT alone did not cause significant body weight changes up to 400 mg/kg. However, AZT at 100, 200, and 400 mg, when given in combination with 100, 200, or 400 mg (1 to 4 times the therapeutic dose) of rifampicin, caused significant decreases in body weights and dose-related increases in mortality. Most mice treated with 400 mg rifampicin in combination with 100, 200, or 400 mg AZT and 200 mg rifampicin with 400 mg AZT died starting at the seventh week of treatment.
Hematological parameters of mice treated with rifampicin alone or in combination with AZT are given in Tables 6 and 7 . Rifampicin alone at 100 mg/kg did not cause consistent and biologically significant hematological changes during the 13-week study. At 200 mg/kg there were statistically significant but not biologically significant decreases in hemoglobin concentrations in male mice after 60 and 92 days of treatment. Rifampicin alone at 400 mg/kg caused significant (p < 0.01) decreases in RBC count and hemoglobin concentration and the severity of these effects increased from Day 60 to Day 92 (Tables 6 and 7) . Rifampicin at 100, 200, and 400 mg caused dose-related decreases (p < 0.01) in reticulocytes in male and 'N = 7.
•^Mice died due to toxicity/anemia during the study. ' N = 4. * Eight of ten mice died and data from the 2 survivers are not included. ' Units are g/dl. 1 Units ore lOVmm 3 . female mice at 4 days but not at other sampling points (data not shown). Coadministration of AZT and nfampicin caused hematological changes as early as Day 4 and by Day 30 there was severe dose-related anemia. By Day 60 most or all mice in the male and female groups given 400 mg nfampicin with 100, 200, or 400 mg of AZT and female group given 200 mg rifampicin with 400 mg AZT died. The major cause of mortality was considered to be treatment-related anemia because the RBC counts and hemoglobin concentrations of these groups, especially female mice at the 30-day sampling, were less than 25% those of the control group (Tables 6 and 7) , and there were no significant changes in hematological parameters of Day 60 samples of control groups subjected to repeated blood sampling on Days 4 and 30. Mortality in the female hematology group treated with AZT 200 mg + rifampicin 200 mg was higher as compared with the 13-week core study group treated with same drug combination ( Table 7) . Hematological toxicity due to treatment exacerbated by repeated blood sampling (at Days 4 and 30) leading to severe anemia appears to be the cause of increased mortality in the above hematology group. The male group treated with AZT 200 mg + rifampicin 200 mg had higher RBC counts and hemoglobin concentrations at the Day 60 sampling than at the Day 30 sampling. The higher hematological values at Day 60 appear to be due to temporary recovery of hematopoietic response of surviving mice as indicated by significant (p < 0.01) and marked reticulocytosis (240% of control) at the Day 30 sampling. However, the above dose combination caused significant and marked decreases in RBC count and hemoglobin concentration with reticulocytopenia (44% of control), leading to severe anemia at the Day 92 sampling (Table 6 ). Combination therapies caused dose-and duration of treatment-related increases in platelet counts with highly significant increases at higher dose combinations leading to thrombocytosis in surviving mice (Tables 6  and 7) . Since thrombocytosis appears to be a unique effect of AZT, the significant increases in platelet counts in AZT + rifampicin groups as compared with the corresponding AZTalone dose groups (Tables 6 and 7) indicate that rifampicin is increasing the biological activity of AZT, leading to increased AZT-associated toxicity. The incidence and severity of bone marrow lesions as indicated by cellular depletion and determined by histopathological evaluation of femoral marrow by light microscopy are listed in Table 8 . AZT alone caused a dose-related loss of hematopoietic cells and rifampicin alone did not cause significant loss of hematopoietic cells of the bone marrow (Table 8) . However, rifampicin at 200 and 400 mg, when coadministered with AZT, caused an increased incidence of bone marrow (Table 8) and splenic cellular depletion at all the dose combinations tested. Histopathological changes in bone marrow as indicated by severity of cellular depletion increased with increasing dose combinations (Table 8) . AZT or rifampicin alone caused doserelated increases in splenic hematopoiesis. Coadministration of AZT and rifampicin also caused an increase in splenic hema- "Number of mice with bone marrow cellular depletion out of 10 mice examined.
* Mean degree of seventy (1 = minimal, S5% depletion; 2 = mild, 6-20% depletion; 3 = moderate, 21-50% depletion; 4 = marked, >50% depletion) of femoral marrow as determined by histopathological evaluation by light microscopy.
c Includes data from 4 mice that died during Weeks 8 to 11. d Includes data from 7 mice that died during Weeks 8 and 9. * Data from Week 7, when all mice in these groups died.
•^Includes data from 8 mice that died during Weeks 8 to 11. * Includes data from 9 mice that died during Weeks 7 and 8. * Data from Weeks 7 and 8, when all the mice in this group died.
topoiesis, except at doses that caused severe anemia and mortality. Rifampicin caused cytoplasmic vacuolization of hepatocytes typical of fat vacuoles that were most prominent in the centrilobular region of the liver. AZT did not influence the hepatocyte alterations caused by rifampicin. Serum alkaline phosphatase (ALP) and alanine aminotransferase (ALT) levels of male and female mice 30, 60, and 92 days after treatment with AZT, rifampicin, and combination therapies are listed in Tables 9 and 10 , respectively. There were no marked changes in the selected serum enzyme parameters on Day 4; therefore, they were not listed in Tables 9 and 10. AZT alone at the doses tested did not cause significant changes in clinical chemistry parameters evaluated in this study. Rifampicin alone caused dose-and duration of treatment-related increases in ALP and ALT activities indicative of hepatic toxicity. Mild dose-and duration of treatment-related increases in aspartate aminotransferase activities (data not shown) were also observed. AZT at the doses tested did not influence the serum enzyme increases caused by rifampicin. When both drugs were given at the estimated therapeutic doses, rifampicin caused a synergistic effect (Eaton and Klaassen, 1994) on the hematological toxicity of AZT, leading to severe anemia. Mortality was observed by 8 weeks when rifampicin and AZT were coadministered at two times the therapeutic doses. Rifampicin caused increases in serum enzyme activities (indicating hepatic toxicity) and hepatocyte alterations at one to four times the therapeutic doses. The synergistic effect of rifampicin on the hematological toxicity of AZT may be related to metabolism of AZT in the liver due to hepatotoxicity of rifampicin.
Interactions of AZT and the Anti-TB Drugs
Interactions of the effect of selected doses of the anti-TB drugs on AZT-induced hematological toxicity as determined by RBC count in female mice 30 days after treatment are presented in Fig. 1 . The RBC counts at 30 days were selected to avoid the complications of dose-related mortalities with some combination therapies after 30 days. The expected combination effect shown in Fig. 1 represents the RBC count of the control group corrected for decreases in RBC count by the selected doses of AZT or the anti-TB drug alone. For example, in the AZT + isoniazid study, the RBC counts 30 days after treatment in female mice were 9.49, 7.15, and 9.18 X 10 6 /mm 3 for the control, 400 mg AZT, and 150 mg isoniazid groups, respectively (Table 5) . At these doses AZT caused a decrease of 2.34 and isoniazid caused a decrease of 0.31 X 10 6 /mm 3 RBC. If the effect is additive, we assumed that the combination of 400 mg AZT with 150 mg isoniazid will decrease the RBC count by 2.65 (2.34 + 0.31) to 6.84 X 10 6 /mm 3 , and this value was shown as the expected combination effect in Fig. 1 . Based on the above assumptions, pyrazinamide at 1500 mg/kg appears to potentiate (Eaton and Klaassen, 1996) the hematological toxicity of AZT at 400 mg (Fig. 1, Table 3 ). Isoniazid at 150 mg/kg and rifampicin at 400 mg/kg increased the hematological toxicity considerably more than a simple additive effect to cause severe anemia (Fig. 1, Tables 5 and 7) , indicating that isoniazid and rifampicin caused potentiation and/or synergism (Eaton and Klaassen, 1996) of the hematological toxicity of AZT.
Isobolographic representation of interactions between each of the three anti-TB drugs and AZT in female mice as determined by RBC count at 30 days is shown in Fig. 2 . The point in each plot locates the dose combination resulting in maximum reduction of RBC count in the three studies reported. The line connecting the Y and X axes, the isobol, locates dose combinations expected to produce the same degree of reduction in RBC count if no interaction between drugs occurred. When the observed response to the tested dose combination falls below the line, as observed for each of the drug combinations illustrated in Fig. 2 , the response to the drug combination is interpreted as synergism or potentiation. In contrast, if the observed response was to fall above the line, the response would be interpreted as antagonism.
In the absence of interaction in the AZT + rifampicin study, a dose of approximately 1200 mg AZT with 400 mg rifampicin will be needed to achieve the observed effect of 400 mg AZT with 400 mg rifampicin. Rifampicin increased the toxicity of AZT by approximately threefold (400 mg instead of 1200 mg). Since rifampicin at the high dose caused some hematological toxicity, the increased hematological toxicity of AZT in the presence of rifampicin can be interpreted as due to synergism (Eaton and Klaassen, 1994) . In contrast, isoniazid did not cause significant hematological toxicity at the doses tested. Nevertheless, 150 mg of isoniazid with 400 mg of AZT markedly increased the hematological toxicity leading to severe anemia. Therefore, isoniazid potentiated (Eaton and Klaassen, 1996) the hematological toxicity of AZT.
Decreases in hemoglobin concentrations in groups treated with various doses of the combination therapies were similar to the decreases in RBC counts. However, at dose combinations that were not highly toxic, the decreases in hemoglobin levels were not as marked as the RBC counts. Since AZT caused macrocytic anemia with increases in MCV and MCH (larger RBC with more hemoglobin/RBC), and most of the observed hematological toxicity of combination therapies appears to be due to enhancement of AZT-associated toxicity, the hemoglobin levels did not decrease as much as the RBC counts at dose combinations that were not highly toxic.
The results of our studies with the B6C3F1 mouse model indicate that (A) the toxic potential for AZT + pyrazinamide combination therapy appears to be very low with a therapeutic index (Roberts and Bourne, 1982; Ottoboni, 1991) of greater than 10, (B) the toxic potential of AZT + isoniazid combination therapy appears to be high with a therapeutic index of less than 4, and (C) the toxic potential of AZT + rifampcin combination therapy appears to be very high with a therapeutic index close to 1 as indicated by significant hematological toxicity (p < 0.01, Table 7 ) at the calculated therapeutic dose combination (100 + 100 mg/kg) in 60 to 92 days. SUMMARY AZT at 1 to 4 times the therapeutic doses caused a doserelated increase in the severity of hematological toxicity. Pyrazinamide at 6.7 and 10 times the therapeutic doses did not cause general or hematological toxicity. However, 10 times the therapeutic dose of pyrazinamide increased the toxicity of 2 times the therapeutic dose of AZT to be equivalent to or greater than 4 times the therapeutic dose of AZT, indicating that pyrazinamide may have potentiated the hematological toxicity of AZT at high doses (Tables 2 and 3 ). Isoniazid at 1 to 3 times the therapeutic doses did not cause hematological or general toxicity. However, 2 times the therapeutic dose of isoniazid increased the toxicity of 1 times the therapeutic dose of AZT. The toxicity of 2 times the therapeutic dose of AZT, when coadministered with 2 times the therapeutic dose of isoniazid, was equivalent to or greater than the toxicity of 4 times the therapeutic dose of AZT. Isoniazid at 3 times the therapeutic dose potentiated the hematological toxicity of AZT at 4 times the therapeutic dose (Tables 4 and 5 ) and appeared to have contributed to mortality of female mice. Rifampicin caused dose-related hematological toxicity at 2 to 4 times the therapeutic doses but not at 1 times the therapeutic dose. However, most or all mice given 400 mg rifampicin with 100, 200, and 400 mg of AZT or 200 mg rifampicin with 400 mg AZT either had severe anemia or died due to anemia (Tables 6 and 7 ), indicating that rifampicin synergized the hematological toxicity of AZT. Hepatocelluar alterations or toxicity caused by the anti-TB drugs pyrazinamide, isoniazid, and rifampicin at the doses evaluated were minimal and appear not to be affected by coadministration of up to 4 times the therapeutic dose of AZT. However, the hematological toxicity of AZT was potentiated or synergized by isoniazid and rifampicin at or close to the therapeutic doses. Rifampicin appears to be the most toxic and pyrazinamide the least toxic of the three anti-TB drugs with regard to potentiation/synergism of hematological toxicity of AZT at or close to the therapeutic doses. Results of these studies indicate that the toxicological effects of combination therapies could be considerably more severe than and different from the toxicity of individual therapies.
